Literature DB >> 2112533

Characteristics of aztreonam as a substrate, inhibitor and inducer for beta-lactamases.

Y Sakurai1, Y Yoshida, K Saitoh, M Nemoto, A Yamaguchi, T Sawai.   

Abstract

Aztreonam was investigated as to its characteristics as a substrate, inhibitor and inducer for the well-defined beta-lactamases of Gram-negative bacteria, and its antibacterial efficacy as to bacterial cells producing eight types of beta-lactamases was also evaluated. Aztreonam was hydrolyzed at measurable rates by class A beta-lactamases, a TEM-2 type penicillinase and the Proteus vulgaris cephalosporinase with a broad substrate range. However, the affinity of aztreonam for the class A enzymes was low, this property being well reflected by its high antibacterial activity toward producers of class A beta-lactamases. Aztreonam was extremely stable as to the typical class C cephalosporinase of Citrobacter freundii, and acted as a competitive and progressive inhibitor for the beta-lactamase. While the MICs of aztreonam in the cases of the constitutive producers of class C beta-lactamases were evidently affected by enzyme production. An experiment involving aztreonam as a inhibitor in combination with a hydrolyzable beta-lactam gave ambiguous results, however, a strong synergistic effect was found in combination with mecillinam. Using Pseudomonas aeruginosa, aztreonam was confirmed to be a poor inducer of beta-lactamases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112533     DOI: 10.7164/antibiotics.43.403

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  6 in total

1.  Genomic Analysis Identifies Novel Pseudomonas aeruginosa Resistance Genes under Selection during Inhaled Aztreonam Therapy In Vivo.

Authors:  Kathryn McLean; Duankun Lee; Elizabeth A Holmes; Kelsi Penewit; Adam Waalkes; Mingxin Ren; Samuel A Lee; Joseph Gasper; Colin Manoil; Stephen J Salipante
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

Review 2.  New β-Lactamase Inhibitors in the Clinic.

Authors:  Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

3.  Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa.

Authors:  P D Lister; W E Sanders; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

4.  Therapeutic Effect and Mechanisms of the Novel Monosulfactam 0073.

Authors:  Ying Sun; Xueyuan Liao; Zhigang Huang; Yaliu Xie; Yanbin Liu; Cuicui Ma; Boguang Jiang; Li Zhang; Yuhang Yan; Guobo Li; Xingjun Cheng; Qi Yin; Charles Z Ding; Liang Shen; Jian Li; Shuhui Chen; Yuquan Wei; Zhenling Wang; Xiawei Wei
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

5.  Pseudomonas aeruginosa: resistance to the max.

Authors:  Keith Poole
Journal:  Front Microbiol       Date:  2011-04-05       Impact factor: 5.640

Review 6.  Antibiotics and Carbohydrate-Containing Drugs Targeting Bacterial Cell Envelopes: An Overview.

Authors:  Federico Riu; Alessandro Ruda; Roberta Ibba; Simona Sestito; Ilenia Lupinu; Sandra Piras; Göran Widmalm; Antonio Carta
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.